Functional microarray analysis suggests repressed cell-cell signaling and cell survival-related modules inhibit progression of head and neck squamous cell carcinoma

Anna EL Coló1,2*, Ana CQ Simoes3, André L Carvalho1, Camila M Melo1, Lucas Fahham4, Luiz P Kowalski1, Fernando A Soares1, Eduardo J Neves4, Luiz FL Reis1.5 and Alex F Carvalho1

Abstract

Background: Cancer shows a great diversity in its clinical behavior which cannot be easily predicted using the currently available clinical or pathological markers. The identification of pathways associated with lymph node metastasis (N+) and recurrent head and neck squamous cell carcinoma (HNSCC) may increase our understanding of the complex biology of this disease.

Methods: Tumor samples were obtained from untreated HNSCC patients undergoing surgery. Patients were classified according to pathologic lymph node status (positive or negative) or tumor recurrence (recurrent or non-recurrent tumor) after treatment (surgery with neck dissection followed by radiotherapy). Using microarray gene expression, we screened tumor samples according to modules comprised by genes in the same pathway or functional category.

Results: The most frequent alterations were the repression of modules in negative lymph node (N0) and in non-recurrent tumors rather than induction of modules in N+ or in recurrent tumors. N0 tumors showed repression of modules that contain cell survival genes and in non-recurrent tumors cell-cell signaling and extracellular region modules were repressed.

Conclusions: The repression of modules that contain cell survival genes in N0 tumors reinforces the important role that apoptosis plays in the regulation of metastasis. In addition, because tumor samples used here were not microdissected, tumor gene expression data are represented together with the stroma, which may reveal signaling between the microenvironment and tumor cells. For instance, in non-recurrent tumors, extracellular region module was repressed, indicating that the stroma and tumor cells may have fewer interactions, which disable metastasis development. Finally, the genes highlighted in our analysis can be implicated in more than one pathway or characteristic, suggesting that therapeutic approaches to prevent tumor progression should target more than one gene or pathway, specially apoptosis and interactions between tumor cells and the stroma.

Background

Head and neck squamous cell carcinomas (HNSCC) are the seventh most common solid malignancy in the United States, accounting for more than 47,000 new cancer cases per year [1]. Surgery of patients clinically diagnosed with lymph node metastasis (N+) usually involves neck dissection, which can cause disfigurement, functional impairment, and pain. However, after histological examination, more than 30% of clinically N+ patients turn out to be pathologically metastasis-free (pN0) [2].

Clinically N0 patients may have occult node metastasis in up to 50% of the cases; in other words, these patients are pathologically N+ (pN+) [3]. Within two years of follow-up, these patients may develop metastatic disease [4]. On the other hand, around 50% of N0 patients do not
not have occult node metastasis. Therefore, many pN0 patients undergo neck dissection unnecessarily. Due to limitations in detecting lymph node metastasis before surgery, both pN+ and pN0 patients may receive inappropriate treatment. This indicates that a better understanding of the biology of HNSCC is urgently needed.

HNSCC also shows a great diversity in its clinical behavior after treatment, which cannot be predicted using the currently available clinical or pathological markers. Despite tumor complexity, many studies have unsuccessfully tested the prognostic value of single genes as markers for HNSCC. The most studied genes related to the onset of HNSCC are epidermal growth factor receptor (EGFR), Cyclin D1, p53, and Human Papilloma Virus (HPV), while the expression of matrix metallopeptidases (MMP) and vascular endothelial growth factor (VEGF) are associated with the metastatic phenotype (for review see references [5,6]). Despite the development of target therapies against EGFR and VEGFR, metastasis affects 40 to 50% of advanced HNSCC patients [7-9].

Microarray studies provide simultaneously measurement of thousands of genes, having therefore been used to identify many differentially expressed genes and expression profiles in HNSCC. For instance, a molecular signature of 102 genes was identified and independently validated for detection of lymph node metastasis with overall accuracy of 86% [10]. Later, numerous combinations of genes were used for predicting lymph node status, suggesting that molecular signatures based on a large number of genes are less likely to be biased towards specific samples [11]. Unfortunately, the use of expression profiles has not been incorporated into the clinic due to a lack of standards in experimental design and heterogeneous results [12].

According to the functional analysis of microarray data described by Segal et al. [13], a group of tumor samples can be characterized according to the behavior of modules. These modules include clusters of genes that belong to the same pathway or functional category [14, 15].

Cancer is a multifaceted phenomenon that involves activation and/or disruption of various cellular processes. Thus, the identification of pathways or groups of genes such as those involved in the development of lymph node metastasis and recurrent disease may help us understand the complex biology of HNSCC.

Previously, our group successfully applied the functional analysis strategy to identify altered modules in pre-malignant and adenocarcinomas of the stomach and esophagus [16]. Here we describe the application of this analysis to screen modules of genes with altered expression in poor prognosis HNSCC (positive lymph node or recurrent tumors). Our findings suggest that progression of HNSCC may be inhibited by loss of expression of genes related to cell survival and interactions with the stroma.

**Methods**

**Patients and tissue samples**

The study was approved by our institutional review board and all patients signed a pre-informed consent. Samples were obtained from surgery of patients with untreated HNSCC at the Head and Neck Surgery and Otorhinolaryngology Department of the Hospital AC Camargo (São Paulo, Brazil) (Table 1). During surgery,
all patients were submitted to neck dissection. No patients received chemotherapy before or after surgery. All patients whose samples were used in the comparison between recurrent versus non-recurrent tumors were treated with adjuvant radiotherapy. Tumor samples were snap-frozen in liquid nitrogen. Before RNA extraction, diagnosis was confirmed by hematoxylin-eosin staining. Frozen samples were hand dissected for removal of normal cells, necrosis, and infiltrating inflammatory cells.

**Microarray expression analysis**

The experimental procedures and raw data are available at the Gene Expression Omnibus, according to the Minimum Information About a Microarray Experiment standards [GEO:GSE22243] [17]. Total RNA was extracted using Trizol (Invitrogen, Carlsbad, CA). RNA quality was assessed by spectrophotometry and gel electrophoresis. To be considered as high-quality, the RNA had to have a 260/280 ratio higher than 1.7 and an 18S/28S rRNA ratio ~2. Amplification of the mRNA was done using a T7-based protocol [18] and cDNA was indirectly labeled with Alexa Dye 555 or 647 (Invitrogen, Carlsbad, CA). Samples and a common RNA reference were hybridized overnight at 42°C in dye-swap to a 4,800-element in-house printed microarray [GEO:GPL8173] [19], enriched with cancer-related ESTs derived from the Human Cancer Genome Project [20], [21]. After washing, slides were scanned on a confocal laser scanner (ScanArray Express, Perkin-Elmer Life Sciences, Boston, MA) and data were extracted with ScanArray Express software.

**Functional modules analysis**

The analysis was carried in R [22], [23] plus Bioconductor’s maigesPack [24]. Background-subtracted spot intensities were normalized by Loess using span 0.4 and degree 2. Next, we searched for gene expression patterns associated with clinical/pathological parameters but which were not necessarily associated with individual samples, following the method described by Segal et al. [13]. For that, we defined functional modules according to the following databases: Biocarta [25], GeneDecks [26], Gene Ontology [27], and Kyoto Encyclopedia of Genes and Genomes Pathway Database (KEGGPD) [28]. 334 modules could be represented by the EST sequences spotted on the microarray chip (Additional File 1).

According to Segal and colleagues [13], a gene in each sample is induced when its expression is two times higher than the average expression in all samples, and is repressed when its expression is two times lower than the same average. Next, we identified the modules in each sample containing a higher than expected fraction of induced or repressed genes. For the corresponding hypothesis test, the fraction of induced and repressed genes within each module in a sample would, under the null hypothesis, show a hypergeometric distribution. The hypergeometric distribution is used to calculate a p-value for this fraction and a 5% FDR is used to correct for multiple testing. Likewise, a module is considered to be induced/repressed in a group of samples when a higher than expected frequency of samples shows induction/repression of the module. Although the size of the modules ranged from 1 to 180 genes, the p-value of altered modules was not related to the number of gene in each of them (Figure 1).

**Quantitative RT-PCR and statistical analysis**

Expression of selected genes from altered modules was analyzed by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) in a ABI Prism® 7300 Sequence Detection System (Applied Biosystems, Foster City, CA). HNSCC patients were classified according to pathologic lymph node status (positive or negative) or tumor recurrence (recurrent or non-recurrent tumor) after treatment (surgery with neck dissection followed by radiotherapy). Gene expression was assessed by microarray and functional module analysis was performed. Functional modules were defined according to the following databases: Biocarta, GeneDecks, Gene Ontology, and to the Kyoto Encyclopedia of Genes and Genomes Pathway Database (KEGGPD). A module is considered to be induced or repressed when it contains a fraction of induced or repressed genes that is higher than expected. The p-value of this fraction was calculated using hypergeometric distribution and a false discovery rate of 5% was applied to correct multiple testing. A - Negative lymph node (pN0). B - Non-recurrent tumors. These figures are representative of those for positive lymph node (pN+) and for recurrent tumors, as well as for the induced modules hypothesis.
City, CA) using 1X SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA). Three constitutive genes (BCR2, HBMS, and HPRT1) were used to calculate a normalization factor through GeNorm [29]. Primer efficiency was used to calculate the relative expression to the RNA reference [30]. Median expression in the analyzed groups was compared using Mann-Whitney test. Logistic regression model was employed to identify independent risk factor for lymph node metastasis (pN+). Kaplan-Meier method was used to analyze recurrence-free survival and curves were compared with the log-rank test. Cox proportional hazards model was employed to identify independent risk factors for recurrence.

Results
Two types of clinical parameters were used to assess the expression pattern of functional modules associated with poor prognosis in HNSCC: lymph node metastasis prior to surgery and recurrence after treatment.

Functional modules related to lymph node metastasis
To analyze the pattern of functional expression associated with lymph node metastasis, samples from primary squamous cell carcinoma of the oral cavity and oropharynx were collected from previously untreated patients and classified according pathologic status as either negative (pN0) or positive (pN+) for lymph node metastasis.

Functional modules analysis was performed, which quantify the enrichment of group of genes in samples profiled by microarray. Specifically, it tests whether the fraction of over- or under-expressed genes in each sample is higher than the randomly expected according to hypergeometric distribution. Next, the analysis assesses whether particular group of samples (such as pN0 or pN+) preferentially over- or under-express a certain module of genes.

Among 334 tested modules, alterations with statistical significance were found in four modules: Kallikrein pathway, Protein binding, Regulation of apoptosis, and Metabolism of xenobiotics by cytochrome P450. As only a subset of genes in a module may contribute to its expression signature, core results are shown in Table 2 (complete list of altered modules and its genes can be found in Additional File 2).

The pN+ group showed repression in the Kallikrein pathway, whereas pN0 tumors showed induction of the same module. The pN0 group also under-express a panel of function-restricted gene related to Protein binding and Regulation of apoptosis (Table 2).

Next, expression of selected genes in altered modules was analyzed by qRT-PCR. Among the genes that most contributed to the repression of modules in the pN0 group, CCL20, EGFR, and INHBA were found to be down-regulated in this group compared to pN+ tumors (Table 3). Moreover, we found that INHBA up-regulation was associated with lymph node metastasis (N+) (odds ratio 5.6; 95% confidence interval 1.5 to 21.8; p-value = 0.012), as well as SERPINA3 down-regulation (odds ratio 4.0; 95% confidence interval 1.0 to 15.4; p-value = 0.044) (Table 4).

Functional modules related to locoregional and distant metastasis
In order to study the expression pattern of functional modules related to poor prognosis we also checked medical records for locoregional recurrence and/or distant metastasis. Follow-up was available for 47 pN+ patients. Twenty of them presented locoregional recurrence and/or distant metastases (biopsy proven or by imaging), and 27 were recurrence/metastasis-free after treatment.

Functional modules analysis showed alterations in the Cell-cell signaling and Extracellular region modules (Table 2, see Additional File 2 for complete list of altered modules). The cell-cell signaling module was repressed in non-recurrent tumors and induced in recurrent tumors. The Extracellular module was also repressed in non-recurrent tumors. As these two modules share same genes, there is an overlap between the genes that most contributed to the repression of both modules.

Using qRT-PCR, we found that BST-2 was down-regulated in recurrent tumors (Table 3). Moreover, BST2 up-regulation was associated with recurrence-free survival (hazard ratio 8.9; 95% confidence interval 1.2 to 68.7; p-value = 0.035) (Table 4).

Discussion
To understand the complex biology of HNSCC, functional analysis of microarray data was used to identify groups of genes involved in the development of lymph node metastasis and recurrence of the disease. We used the strategy proposed by Segal et al [13] because, unlike other functional strategies, this analysis is not restricted to the identification of enriched modules from a list of differentially expressed genes; the functional modules analysis is capable of identifying which modules are induced or and which are repressed in each group of samples. In addition, our findings show that the use of existing biological knowledge in the form of module of genes is valuable tool for understanding tumors with different prognosis. The functional modules strategy characterized each condition by a particular combination of modules, providing important insights into the gene expression of primary tumors of patients with lymph node metastasis and recurrent disease. For
| Module                          | Status      | Gene symbol | p-value |
|--------------------------------|-------------|-------------|---------|
| **Negative lymph node (20 samples)** |             |             |         |
| Protein biding                 | repressed   | FOSB        | 4.1E-31 |
|                                |             | KLK6        | 5.7E-18 |
|                                |             | AREG        | 1.3E-11 |
|                                |             | CCL20       | 4.0E-08 |
|                                |             | IL1B        | 7.5E-05 |
|                                |             | MYC         | 2.0E-04 |
|                                |             | INHBA       | 7.0E-03 |
|                                |             | EGFR        | 1.4E-02 |
|                                |             | AKT1        | 2.1E-02 |
| Regulation of apoptosis        | repressed   | SPHK1       | 9.0E-09 |
|                                |             | INHBA       | 9.0E-09 |
|                                |             | AKT1        | 9.7E-03 |
| KLK pathway                    | induced     | KLK13       | 4.0E-15 |
|                                |             | KLK7        | 2.8E-05 |
|                                |             | KLK6        | 1.5E-02 |
|                                |             | SERPINA3    | 1.7E-02 |
| **Positive lymph node (61 samples)** |             |             |         |
| KLK pathway                    | repressed   | KLK13       | 4.0E-15 |
|                                |             | KLK7        | 2.8E-05 |
|                                |             | KLK6        | 1.5E-02 |
|                                |             | SERPINA3    | 1.7E-02 |
| **Recurrent tumors (20 samples)** |             |             |         |
| Cell-cell signaling            | induced     | IL1F9       | 4.1E-20 |
|                                |             | AREG        | 5.5E-15 |
|                                |             | INHBA       | 1.5E-12 |
|                                |             | BST2        | 7.6E-10 |
|                                |             | CCL20       | 2.1E-03 |
|                                |             | KLK6        | 8.9E-3  |
| **Non-recurrent tumor (27 samples)** |             |             |         |
| Cell-cell signaling            | repressed   | IL1F9       | 4.1E-20 |
|                                |             | AREG        | 5.5E-15 |
|                                |             | INHBA       | 1.5E-12 |
|                                |             | BST2        | 7.6E-10 |
|                                |             | CCL20       | 2.1E-03 |
|                                |             | KLK6        | 8.9E-3  |
| Extracellular region           | repressed   | INHBA       | 6.6E-15 |
|                                |             | POSTN       | 3.0E-9  |
|                                |             | KLK13       | 1.9E-6  |
|                                |             | AREG        | 2.4E-6  |
|                                |             | MMP13       | 7.3E-4  |
|                                |             | KLK6        | 1.6E-2  |

HNSCC patients were classified according to pathologic lymph node status (positive or negative) or tumor recurrence (recurrent or non-recurrent tumor) after treatment (surgery with neck dissection followed by radiotherapy) and samples from primary tumors were collected. Gene expression was assessed by microarray and functional module analysis was performed. Functional modules were defined according to the following databases: Biocarta, GeneDecks, Gene Ontology, and to the Kyoto Encyclopedia of Genes and Genomes Pathway Database (KEGGPD).
instance, the altered modules harbor genes that are frequently studied in cancer but also suggest a role for some genes that have not been previously implicated in HNSCC or metastasis in general. Based on the literature and on the pathways presented by KEGGPD, many connections between these genes could be highlighted (Figure 2). These connections are summarized below.

Samples from patients with negative lymph node showed induction of the Kallikrein pathway. SERPINA3 belongs to the Kallikrein pathway, which is induced in pN0 tumors. SERPINA3 encodes the protease inhibitor alpha-1-antichymotrypsin, which was previously reported to inhibit MMP9 activation [31].

The protein binding module is repressed in pN0 tumors. INHBA belongs to the Kallikrein pathway, which is induced in pN0 tumors. INHBA encodes the protease inhibitor alpha-1-antichymotrypsin, which was previously reported to inhibit MMP9 activation [31].

Table 3 Expression of genes found in altered modules of head and neck squamous cell carcinoma (HNSCC) assessed by quantitative reverse transcription-polymerase chain reaction (qRT-PCR)

| Comparison          | Gene  | \textit{p}-value, Mann-Whitney test | Fold change |
|---------------------|-------|------------------------------------|-------------|
| Positive lymph node (61 samples) | CCL20 | 0.009 | 3.40 |
| Negative lymph node (20 samples) | EGFR | 0.006 | 1.70 |
|                     | INHBA | 0.014 | 2.05 |
|                     | IL1B  | 0.07 | 1.38 |
|                     | SERPINA3 | 0.07 | -2.43 |
|                     | AKT1  | 0.13 | - |
|                     | MYC   | 0.17 | - |
|                     | MCM2  | 0.22 | - |
|                     | AREG  | 0.41 | - |
|                     | PCNA  | 0.43 | - |
|                     | KLK6  | 0.45 | - |
|                     | FOSB  | 0.59 | - |
| Recurrent tumors (20 samples) | BST2 | 0.014 | -1.70 |
| Non-recurrent tumors (27 samples) | POSTN | 0.058 | 2.47 |
|                     | IL1F9 | 0.061 | 1.91 |
|                     | CCL20 | 0.19 | - |
|                     | INHBA | 0.55 | - |
|                     | AREG  | 0.67 | - |
|                     | KLK6  | 0.76 | - |

HNSCC patients were classified according to pathologic lymph node status (positive or negative) or tumor recurrence (recurrent or non-recurrent tumor) after treatment (surgery with neck dissection followed by radiotherapy) and samples from primary tumors were collected. Gene expression was assessed by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Logistic regression model was employed to identify independent risk factor for lymph node metastasis (pN+). Logistic regression model was employed to identify independent risk factors for recurrence.

Epithelial growth factor receptor (EGFR), which has shown to be overexpressed in HNSCC in several studies, plays a critical role in HNSCC growth, invasion, metastasis, and angiogenesis (for review see reference [5]). Amphiregulin, the protein encoded by AREG, is a ligand of EGFR. In squamous cell carcinoma cells, amphiregulin is released by MMP cleavage. Moreover, AREG gene silencing or binding inhibition prevents EGFR phosphorylation and downstream events, such as cell proliferation, migration, and activation of the survival mediator AKT [39]. CCL20, the macrophage inflammatory protein-3α, mediates ERK1/2 activation through a MMP-dependent release of amphiregulin and transactivation of the EGFR. Again, blockade of amphiregulin reduced CCL20-mediated cell proliferation [40].

Considering these findings, we suggest that the tumor biology of pN0 is associated with repression of modules (AKT) pathway [33]. SPHK1 is a kinase that may promote growth proliferative advantage and resistance to apoptosis through activation of the extracellular signal-related kinases 1/2 (ERK1/2) and phosphatidylinositol 3-kinase 3-kinase (PI3K)/AKT pathways [34]. SPHK1 can also be activated by IL-1β [35]. IL1F9 gene is in the same locus as IL1B, suggesting a common origin [36]. IL1F9 promotes a signaling cascade similar to IL-1, activating NF-κB [37]. Cell survival is also represented here by AKT1, which phosphorylates and inactivates the apoptotic machinery (for review see reference [38]).
and genes related to proliferation and cell survival, which may be an important factor in lymph node involvement as apoptosis is one of the processes regulating metastasis (for review see reference [41]).

Gene expression profile of metastatic HNSCC has been recently described, and the most significantly altered transcripts in metastatic HNSCC were found to be associated with adhesion, mobility, and cell survival [42]. In our study non-recurrent tumors showed significantly repressed modules, namely cell-cell signaling and extracellular region, which contains POSTN. POSTN encodes periostin, which was implicated in several cellular functions in cancer. Periostin expression in vitro leads to EGFR and MMP9 expression [43]. Periostin may play a role in focal adhesion [44], and promote Akt activation, leading to tumor and endothelial cell survival [45]. Periostin may also be important in the epithelial-mesenchymal transition (EMT). POSTN expression led to EMT phenotype along with enhanced cell migration, invasion, and adhesion [43]. In HNSCC cell lines, periostin promoted distant and lymph node metastases in a murine model [46]. Periostin is also related to angiogenesis. In oral SCC, periostin+ samples had higher blood vessel density and recombinant periostin enhanced blood vessel formation in vitro [47]. Finally, it was shown that periostin is expressed by stromal cells [48] and by fibroblasts in cancer [49]. Therefore, it is possible that in non-recurrent tumors, in which the POSTN module is repressed, the stroma has fewer interactions with tumor cells, somehow disabling metastasis development.

One limitation of this study was that the connections among genes based on information from the literature were collected through different types of experiments done in several forms of cancer. Therefore, we cannot be sure that these connections really occur in HNSCC. These findings need to be validated by functional assays to assess the role they might have in complex and heterogeneous cancer cells. Moreover, the modules identified as induced or repressed were groups of genes that...
belong to the same functional category which do not necessarily represent pathways. However, according to Segal et al [13], many phenomena are sufficiently robust to be detected using functional modules analysis. So, the repression of functional categories may suggest that the main differences between two types of tumors (e.g. N0 and N+) are not in pathways per se, but in cellular functions instead.

In this study, we focused on the biology of the altered modules in pN0 vs. pN+ and in recurrent vs. non-recurrent tumors. The great advantage of the functional modules strategy is the increased comparability of results from different microarray studies [50]. Indeed, we identified altered modules with functions similar to those described by other authors using different approaches of functional gene expression in HNSCC. These functions include cell adhesion, cell death, cell growth and degradation of the extracellular matrix [10]. Up-regulation of genes that encode for MMP and for proteins related to inflammatory response was also found [12]. A supervised pathway-based analysis was performed in pN0 and pN+ HNSCC, indicating gene sets involved in extracellular matrix remodeling, hypoxia, and angiogenesis [50].

Three interesting observations can also be extrapolated from our dataset. First, the most frequent alterations found were the repression of modules in pN0 and in non-recurrent tumors. This also suggests that loss of various cellular functions may have a negative effect on the acquisition of the metastatic phenotype. Secondly, the tumor samples used here are not microdissected, so the data represent the gene expression of the tumor together with the stroma. Thus, the genes responsible for induction/repression of modules may show signaling between the microenvironment and the tumor cell. The understanding of how these interactions lead to tumor progression is critical for improving cancer treatment. Finally, many of the genes can be implicated in more than one pathway or more than one characteristic. Therefore, therapeutic approaches to prevent tumor progression should target more than one gene or pathway.

Functional modules analysis also provided interesting putative biomarkers that have not been previously implicated in HNSCC lymph node metastasis or recurrence. For instance, BST2 up-regulation was significantly associated with disease-free survival. BST2, also known as bone marrow stromal cell antigen 2, was implicated in many cellular functions in different cell types, such as development of B cell precursors [51], actin organization at the apical membrane of epithelial cells [52], and tethering HIV virions to cells [53]. Although BST2 function in HNSCC is unknown, BST2 expression may be used as prognostic marker to guide treatment. In addition, we found that INHBA up-regulation and SERPINA3 down-regulation are significantly associated with lymph node metastasis. This information would be very useful in routine care of HNSCC because the presence of lymph node metastasis prior to surgery is not easily determined by the currently available methods.

Conclusions
The alterations identified here offer a comprehensive initial view of the molecular mechanisms of HNSCC, suggesting that loss of cell survival and interactions with the stroma inhibits HNSCC progression. Functional and/or in vivo studies may determine which genes, pathways, and gene set combinations have the greatest impact on cancer progression, which may contribute for the improvement of HNSCC treatment.

Additional material
Additional File 1: Genes and modules present in microarray platform GPL8173. List of all modules represented in the microarray platform and the complete list of genes in each represented module.

Additional File 2: Complete list of altered modules found in altered modules of head and neck squamous cell carcinoma (HNSCC). List of all altered modules and all genes representing them in HNSCC classified according to pathologic lymph node status (positive or negative) or tumor recurrence (recurrent or non-recurrent tumor).

Acknowledgements
Grant support: CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico) (LFL Reis and EJ Neves) and FAPESP (Fundação de Amparo à Pesquisa do Estado de São Paulo) grant CEPIX 09/14335-2 (FA Soares and LP Kowalski). AEL Coló was funded with an MSc fellowship from FAPESP and a PhD fellowship from CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior). ACQ Simoes was funded with a PhD fellowship from FAPESP and CAPES and CM Melo with an MSc fellowship from CAPES. We thank Hugo Campos for dissection of tumor samples, Louise Mota, Mariana Santos, Sarah Marques, and Bianca Barreto for technical assistance, the Ludwig Institute for Cancer Research for microarray slides, and Helena Brentani’s lab (Luiz Paulo Camargo, Diogo Patrão, Renato Puga, Artur Fabr, César Torres, Fabio Mathias) for helping with clinical information database, analyzing microarray quality, and submitting microarray data to public databases. The authors are grateful to Núcleo de Modelagem Estocástica e Complexidade of the University of São Paulo (NUMEC/USP) for its support. We also thank Karina Ribeiro for statistical analysis and Marcia Triunfo for critical reading of the article.

Author details
1Hospital AC Camargo, Rua Taguá, 440, São Paulo, SP, 01508-010, Brazil. 2Hospital Israelita Albert Einstein, Avenida Albert Einstein, 627, São Paulo, SP, 05652-900, Brazil. 3Universidade Federal do ABC, Rua Santa Adélia, 166, Santo André, SP, 09210-170, Brazil. 4Instituto de Matemática e Estatística da Universidade de São Paulo, Rua do Matão, 1010, São Paulo, SP, 05508-090, Brazil. 5Hospital Sírio-Libanês, Rua Adma Jafet, 91, São Paulo, SP, 01308-050, Brazil.

Authors’ contributions
AELC participated in the collection of clinical information, carried out the microarray experiments, participated in the data analysis and drafted the manuscript. ACQS organized and performed data analysis, and reviewed the manuscript. ALC participated in the collection of samples and clinical information, and helped in the interpretation of results. QMM helped in the experimental assays. LF participated in data analysis. LPK participated in the
collection of samples and clinical information, and reviewed the manuscript. FAS helped in the collection of samples. EJN coordinated data analysis. LFLR conceived of the study and helped in the interpretation of results. AFC participated in the design and in the coordination of the study. All authors read and approved the final manuscript.

Authors’ information

Current Addresses:

ALC: Hospital São Lucas Albert Einstein, Rua 23 de Maio, 1355, São Paulo, 22451-090, Brazil
GKB: The Royal Marsden Hospital, Fulham Palace Road, London, SW6 6AL, United Kingdom
LFLR: Hospital São Lucas Albert Einstein, Rua 23 de Maio, 1355, São Paulo, 22451-090, Brazil

Competing interests

The authors declare that they have no competing interests.

Received: 27 August 2010 Accepted: 13 April 2011

References

1. Jemal A, Siegel R, Ward E, Hao YP, Xu JQ, Thun MJ. Cancer Statistics, 2009. Cancer Journal for Clinicians 2009, 59(4):225-249.
2. Halberal L, Geller G, Goeman H, Alkansu H, Yousk M, Ozen C. Which is important in the evaluation of metastatic lymph nodes in head and neck cancer: Palpation, ultrasonography, or computed tomography? Otolaryngology-Head and Neck Surgery 2004, 130(2):197-201.
3. Shoaib T, Soutar DS, MacDonald DG, Camilleri KG, Dunaway DJ, Gray HW, McCunnagh GM, Bessent RG, MacLeod TIF, Robertson AG. The accuracy of head and neck carcinoma sentinel lymph node biopsy in the clinically NO neck. Cancer 2001, 91(11):2077-2083.
4. Khafif RA, Gelbfish GA, Tepper P, Attie JN. Elective Radical Neck Dissection in Epidermoid Cancer of The Head and Neck - A Retrospective Analysis of 853 Cases of Mouth, Pharynx, and Larynx Cancer. Cancer 1991, 67(1):67-71.
5. Chang SS, Califano J. Current status of biomarkers in head and neck cancer. Journal of Surgical Oncology 2008, 97(8):640-645.
6. Howell GMS, Grandis JR. Molecular mediators of metastasis in head and neck squamous cell carcinoma. Head and Neck-Journal for the Sciences and Specialties of the Head and Neck 2005, 27(8):710-717.
7. Fischer DG, Su YB, Kraus DH, Wolden SL, Lis E, Aliff TB, Zahalsky AJ, Lake S, Needle MN, Shaha AR, Shah JP, Zelefsky MJ. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: A pilot phase II study of a new combined-modality paradigm. Journal of Clinical Oncology 2006, 24(7):1072-1078.
8. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Needle MN, Shaha AR, Shah JP, Zelefsky MJ. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: A pilot phase II study of a new combined-modality paradigm. Journal of Clinical Oncology 2006, 24(7):1072-1078.
9. Bonner JA, Harati PM, Giralt J, Azamia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassim J, Ove R, Kies MS, Baslega J, Youssoufian H, Aernell N, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. New England Journal of Medicine 2006, 354(6):567-578.
10. Sewert NY, Haraf DJ, Cohen EEW, Stolz PA, Cvetkovic MM, Shaller WD, Willows S, Zago MA, Bordin S, Costa FF, Goldman GH, Carvalho AF, Matsuukuma A, Baas GS, Simpson DH, Brunstein A, de Oliveira PS, Bucher P, Jungenele CJ, O’hare MJ, Soares F, Brentani RR, RS LF, de Souza SJ, Simpson AJ. Shotgun sequencing of the human transcriptome with ORF expression arrays in cancer research: methods and applications. Crit Rev Oncol Hematol 2010, 54(2):95-105.
11. Camargo AA, Sampaia HPD, Dias-Neto E, Samao DF, Cristo EB, Hirata R, Martins EA, Noreiga MP, Paco-Larson ML, Pardini MI, Pereira GG, Pesquero JB, Rodrigues V, Rosato SA, et al. The contribution of 700,000 ORF sequence tags to the definition of the human transcriptome. Proceedings of the National Academy of Sciences of the United States of America 2001, 98(21):12103-12108.
12. Neto ED, Correia RG, Verjovsky-Almeida S, Briones MRS, Nagai MA, da Silva W, Zago MA, Bordim S, Costa FF, Goldman GH, Carvalho AF, Matsukuma A, Baas GS, Simpson DH, Brunstein A, de Oliveira PS, Bucher P, Jungenele CJ, O’hare MJ, Soares F, Brentani RR, RS LF, de Souza SJ, Simpson AJ. Shotgun sequencing of the human transcriptome with ORF expression arrays in cancer research: methods and applications. Crit Rev Oncol Hematol 2010, 54(2):95-105.
13. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge YC, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, K打g H, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smyth G, Tierney L, Yang Y, Zhang J. Biocoda: open software development for computational biology and bioinformatics. Genome Biology 2004, 5(10).
14. Heathcote M, Goto S, Kawashima S, Nakaya A. The KEGG databases at GenomeNet. Nucleic Acids Research 2002, 30(1):42-46.
15. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Isser-Tarver L, Kasukinis A, Lewis S, Mates JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G. Gene Ontology: tool for the unification of biology. Nature Genetics 2000, 25(1):25-29.
16. Camargo AA, Sampaia HPD, Dias-Neto E, Samao DF, Cristo EB, Hirata R, Martins EA, Noreiga MP, Paco-Larson ML, Pardini MI, Pereira GG, Pesquero JB, Rodrigues V, Rosato SA, et al. The contribution of 700,000 ORF sequence tags to the definition of the human transcriptome. Proceedings of the National Academy of Sciences of the United States of America 2001, 98(21):12103-12108.
17. Neto ED, Correia RG, Verjovsky-Almeida S, Briones MRS, Nagai MA, da Silva W, Zago MA, Bordim S, Costa FF, Goldman GH, Carvalho AF, Matsukuma A, Baas GS, Simpson DH, Brunstein A, de Oliveira PS, Bucher P, Jungenele CJ, O’hare MJ, Soares F, Brentani RR, RS LF, de Souza SJ, Simpson AJ. Shotgun sequencing of the human transcriptome with ORF expression arrays in cancer research: methods and applications. Crit Rev Oncol Hematol 2010, 54(2):95-105.
18. Kanehisa M, Goto S, Kawashima S, Nakaya A. The KEGG databases at GenomeNet. Nucleic Acids Research 2002, 30(1):42-46.
19. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Isser-Tarver L, Kasukinis A, Lewis S, Mates JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G. Gene Ontology: tool for the unification of biology. Nature Genetics 2000, 25(1):25-29.
an oncogenic event in erythroleukemic progression. *Blood* 2005, 106(5):1808-1816.

35. Mastrandrea LD, Sessanna SM, Laychock SG: Sphingosine kinase activity and sphingosine-1 phosphate production in rat pancreatic islets and INS-1 cells - Response to cytokines. *Diabetes* 2005, 54(5):1429-1436.

36. Nicklin MJH, Barton JL, Nguyen M, FitzGerald MG, Duff GW, Komman K: A sequence-based map of the nine genes of the human interleukin-1 cluster. *Genomics* 2002, 79(5):718-725.

37. Tovene JE, Garka KE, Hempshaw BR, Virca GD, Sims JE: Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappa B and MAPKs. *Journal of Biological Chemistry* 2004, 279(14):13677-13688.

38. Bussink J, van der Kogel AJ, Kaanders J: Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. *Lancet Oncology* 2008, 9(3):288-296.

39. Gschwind A, Hart S, Fischer OA, Ullrich A: Macrophage-inflammatory protein-3 alpha mediates epidermal growth factor receptor transactivation and ERK1/2 MAPK signaling in Caco-2 colonic epithelial cells via metalloproteinase-dependent release of amphiregulin. *Journal of Immunology* 2007, 178(12):6013-6021.

40. Keates S, Han XB, Kelly CP, Keates AC: TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. *Embo Journal* 2003, 22(10):2411-2421.

41. Rickman DS, Millon R, De Reynies A, Thomas E, Wasylyk C, Muller D, Abecassis J, Wasylyk B: Prediction of future metastasis and molecular characterization of head and neck squamous-cell carcinoma based on transcriptome and genome analysis by microarrays. *Oncogene* 2008, 27(21):6607-6623.

42. Yan W, Shao R: Transduction of a mesenchyme-specific gene periostin into 293T cells induces cell invasive activity through epithelial-mesenchymal transformation. *Journal of Biological Chemistry* 2006, 281(28):19700-19708.

43. Gillan L, Matei O, Fishman DA, Gerbin CS, Karlan BY, Chang DD: Periostin secreted by epithelial ovarian carcinoma is a ligand for alphav/beta(3) and alphav/vibeta(5) integrins and promotes cell motility. *Cancer Research* 2002, 62(18):5358-5364.

44. Bao SD, Ouyang G, Bai XT, Huang Z, Ma CY, Liu M, Shoo R, Anderson RM, Rich JN, Wang XF: Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. *Cancer Cell* 2004, 5(4):329-339.

45. Kudo Y, Ogawa I, Kitajima S, Kitagawa M, Kawai H, Gaffney PM, Miyachi M, Takata T: Periostin promotes invasion and anchorage-independent growth in the metastatic process of head and neck cancer. *Cancer Research* 2006, 66(14):6928-6935.

46. Sinwardena B, Kudo Y, Ogawa I, Kitagawa M, Kitajima S, Harano H, Tilakaratne WM, Miyachi M, Takata T: Periostin is frequently overexpressed and enhances invasion and angiogenesis in oral cancer. *British Journal of Cancer* 2006, 95(10):1396-1403.

47. Tilman G, Mattiussi M, Brasseur F, van Baren N, Decottignies A: Human periostin gene expression in normal tissues, tumors and melanoma: evidences for periostin production by both stromal and melanoma cells. *Molecular Cancer* 2007, 6.

48. Kikuchi Y, Kashima TG, Nishiyama T, Shimazu K, Morishita Y, Shimazaki M, Itoh M, Ochi T, Ishihara K, Hirano T: The tetherin-RICH2 complex plays a critical role in the organization of the subapical actin cytoskeleton in polarized epithelial cells. *J Cell Biol* 2009, 184(5):721-736.

53. Perez-Caballero D, Zang T, Ebrahimi A, McNatt MW, Gregory DA, Johnson MC, Bieniasz PD: Tetherin inhibits HIV-1 release by directly tethering virions to cells. *Cell* 2009, 139(3):499-511.

Pre-publication history
The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1755-8794/4/33/prepub

doi:10.1186/1755-8794-4-33

Cite this article as: Colò et al.: Functional microarray analysis suggests repressed cell-cell signaling and cell survival-related modules inhibit progression of head and neck squamous cell carcinoma. *BMC Medical Genomics* 2011 4:33.

Submit your next manuscript to BioMedCentral and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit